Basal cell carcinoma - Pipeline Insight, 2021

Basal cell carcinoma - Pipeline Insight, 2021

  • October 2021 •
  • 70 pages •
  • Report ID: 6036524 •
  • Format: PDF
“Basal cell carcinoma - Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Basal cell carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Basal cell carcinoma Understanding

Basal cell carcinoma: Overview
Basal cell carcinoma (BCC) is a common, locally invasive, keratinocyte cancer (also known as nonmelanoma cancer). It is the most common form of skin cancer. BCC is also known as rodent ulcer and basalioma. The main characteristics are: Slowly growing plaque or nodule, Skin colored, pink or pigmented, Varies in size from a few millimeters to several centimeters in diameter, Spontaneous bleeding or ulceration. Ultraviolet (UV) rays from the sun or from a tanning bed are the main cause of basal cell carcinoma. The goal of treatment for basal cell carcinoma is to remove the cancer completely. The clinical appearance, size, site, and histologic subtype determine choice of treatment: curettage and electrodesiccation, surgical excision, cryosurgery, topical chemotherapy (imiquimod or 5-fluorouracil) and photodynamic therapy, or, occasionally, radiation therapy. Large or recurrent basal cell cancers are treated best with Mohs’ surgery (a specialized type of microscopically controlled surgery).

"Basal cell carcinoma - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Basal cell carcinoma pipeline landscape is provided which includes the disease overview and Basal cell carcinoma treatment guidelines. The assessment part of the report embraces, in depth Basal cell carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Basal cell carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Basal cell carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Basal cell carcinoma.

Basal cell carcinoma Emerging Drugs Chapters
This segment of the Basal cell carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Basal cell carcinoma Emerging Drugs
• Patidegib: PellePharm
Patidegib is an investigational small molecule that inhibits hedgehog signaling. It is a topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently evaluated in Phase III clinical trials for the treatment of BCCs.

• AIV001: AiViva BioPharma
AIV001 is a novel formulation of a multi-kinase inhibitor combined with AiViva’s proprietary delivery technology, designed for prolonged drug release via intradermal treatment. AIV001 targets multiple pathways to reduce fibroplasia in overlapping phases of wound healing and scarring; targets VEGFR to limit the inflammation and fibrosis associated with rosacea; and inhibits or reduces neovascularization and cell proliferation associated with certain cancers. AIV001 is in Phase I/II clinical studies for the treatment of patients with Basal Cell Carcinoma.
Further product details are provided in the report……..

Basal cell carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Basal cell carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Basal cell carcinoma
There are approx. 25+ key companies which are developing the therapies for Basal cell carcinoma. The companies which have their Basal cell carcinoma drug candidates in the most advanced stage, i.e. Phase III include, PellePharm.

• Phases
This report covers around 25+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Basal cell carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Basal cell carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Basal cell carcinoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Basal cell carcinoma drugs.

Basal cell carcinoma Report Insights
• Basal cell carcinoma Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Basal cell carcinoma Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Basal cell carcinoma drugs?
• How many Basal cell carcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Basal cell carcinoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Basal cell carcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Basal cell carcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• PellePharm
• MedC Biopharma Corporation
• AiViva BioPharma
• MediWound
• Kintara Therapeutics
• IO Biotech
• Sirnaomics
• Aresus Pharma
• Epitome Pharmaceuticals
• Transgene
• Senhwa Biosciences
• Palvella Therapeutics
• Suzhou Kintor Pharmaceuticals
• Leaf Vertical

Key Products
• AIV001
• Patidegib
• MDC-2060
• MWPC 005
• Rostaporfin
• IO103
• STP 705
• Polyphenon E
• AIV 001
• TG 1042
• Silmitasertib
• Sirolimus topical
• GT 1708F
• Cannabidiol